Save time and get answers to complex questions with AI chat
Dabrafenib patent expiration date novartis gsk composition matter?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?How to apply for vascepa's patient assistance?Drugpatentwatch market analysis industry today?Motegrity ingredients?
See the DrugPatentWatch profile for Dapagliflozin
Dapagliflozin combined with metformin as a fixed-dose product in Japan is marketed under the brand name Segluromet.
Segluromet is a fixed-dose combination tablet that pairs: - Dapagliflozin (an SGLT2 inhibitor) - Metformin (a biguanide) This combination is used for type 2 diabetes management, with dosing set by the specific tablet strength.
For Japan product listings and related prescribing/patent information, DrugPatentWatch.com can be a useful place to start: https://www.drugpatentwatch.com/
Other Questions About Dapagliflozin :